5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome

This study is ongoing, but not recruiting participants.
Celgene Corporation
Information provided by (Responsible Party):
Virginia Commonwealth University
ClinicalTrials.gov Identifier:
First received: July 22, 2008
Last updated: March 19, 2015
Last verified: March 2015

Patients with high risk myelodysplastic syndrome (MDS) responding to 5-azacytidine prior to allogeneic transplant have improved event free and overall survival.

Condition Intervention Phase
Myelodysplastic Syndrome
Drug: 5-azacytidine
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of the Use of 5-Azacytidine as Pre-Transplant Cytoreduction Prior to Allogeneic Stem Cell Transplantation for High Risk Myelodysplastic Syndromes

Resource links provided by NLM:

Further study details as provided by Virginia Commonwealth University:

Primary Outcome Measures:
  • 1 year and 2-year event free and overall survival (EFS and OS) from the time of transplant. [ Time Frame: 3 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Secondary endpoints will include intent to treat analysis of 1-year and 2-year EFS and OS for all patients receiving 5-Azacytidine from the time of initial therapy as well as engraftment of WBC and platelets, graft failure, relapse and GVHD. [ Time Frame: 3 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 75
Study Start Date: July 2008
Estimated Study Completion Date: December 2015
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Drug: 5-azacytidine
The recommended starting dose for the first treatment cycle, for all patients regardless of baseline hematology laboratory values, is 75 mg/m2 subcutaneously or intravenously, daily for 7 days.

Detailed Description:

The study drug, 5-azacytidine, is given daily intravenously for 7 days. After every 2 cycles study participants will have a bone marrow test to evaluate the effect of the 5-azacytidine on the Myelodysplastic Syndrome (MDS). Participants continue to get cycles of 5-Azacytidine until 2 bone marrow tests show the MDS has stopped responding to the treatment. At that time they will undergo a transplant if a donor is available.


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients fulfilling the following criteria will be eligible for study entry:

    1. Diagnosis of MDS according to WHO criteria
    2. Intermediate-2 or high risk by IPSS score
    3. Clinically able to receive 5-Azacytidine
    4. Serum bilirubin levels </=1.5 times the upper limit of the normal range for the laboratory (ULN). Higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesis
    5. Serum glutamic-oxaloacetic transaminase (SGOT) or serum glutamic-pyruvic transaminase (SGPT) levels </=2 x ULN
    6. Serum creatinine levels </=1.5 x ULN
    7. Negative serum pregnancy test prior to 5-Azacytidine treatment for women of childbearing potential
    8. Women and men of childbearing potential agree to use contraception while receiving treatment with 5-Azacytidine
    9. Potentially eligible for allogeneic transplantation
    10. No prior allogeneic transplant
    11. Age 18 to 70, inclusive.

Exclusion Criteria:

  1. Known or suspected hypersensitivity to 5-azacytidine or mannitol
  2. Patients previously treated with 5-azacytidine or deoxyazacytidine
  3. Pregnant or breast feeding
  4. Patients with advanced malignant hepatic tumors
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00721214

United States, Virginia
Massey Cancer Center / Virginia Commonwealth University
Richmond, Virginia, United States, 23298
Sponsors and Collaborators
Virginia Commonwealth University
Celgene Corporation
Study Chair: John M. McCarty, MD Virginia Commonwealth University
  More Information

No publications provided

Responsible Party: Virginia Commonwealth University
ClinicalTrials.gov Identifier: NCT00721214     History of Changes
Other Study ID Numbers: MCC-11328
Study First Received: July 22, 2008
Last Updated: March 19, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by Virginia Commonwealth University:
Myelodysplastic Syndrome
allogeneic stem cell transplantation

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Bone Marrow Diseases
Hematologic Diseases
Pathologic Processes
Precancerous Conditions
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on July 30, 2015